Vascular Subphenotypes of Lung Disease in HIV & COPD (VAST)

This study is currently recruiting participants.

Verified April 2012 by University of Pittsburgh

Sponsor:

Information provided by (Responsible Party):

University of Pittsburgh

ClinicalTrials.gov Identifier:

NCT01581086

First received: April 17, 2012

Last updated: April 19, 2012

Last verified: April 2012

History of Changes

Tracking Information

First Received Date ^ICMJE

April 17, 2012

Last Updated Date

April 19, 2012

Start Date ^ICMJE

January 2012

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

Not Provided

Original Primary Outcome Measures ^ICMJE

Not Provided

Change History

Complete list of historical versions of study NCT01581086 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Vascular Subphenotypes of Lung Disease in HIV & COPD

Official Title ^ICMJE

Identify and Characterize Populations at Risk for Developing Pulmonary Arterial Hypertension (PAH)

Brief Summary

This study is looking for high blood pressure in the lungs (Pulmonary artery hypertension PAH) in HIV and COPD patients.

Detailed Description

Not Provided

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Observational Model: Cohort
Time Perspective: Retrospective

Target Follow-Up Duration

Not Provided

Biospecimen

Retention: Samples With DNA

Description:

Whole Blood

Sampling Method

Non-Probability Sample

Study Population

Pitt mens Study(MACS).

University of Pittsburgh HIV Clinic(PACT).

Emphysema COPD Research Center Research Registry(ECRC).

Condition ^ICMJE

Pulmonary Artery Hypertension

Intervention ^ICMJE

Not Provided

Study Group/Cohort (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Recruiting

Estimated Enrollment ^ICMJE

140

Estimated Completion Date

January 2014

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Male/Female 18-80 years of age.
Subject has been previously enrolled in PACT/MAC/ECRC study.
Must have recent ProBNP test >120pg/ml or abnormal echocardiogram (right ventricular systolic pressure >or=40mmHg) without evidence of left sided heart failure.

Exclusion Criteria:

Previous diagnosis of congenital heart failure.
If evidence of Left ventricular systolic or diastolic dysfunction, echo will be reviewed by the PI on a case by case basis.
Creatine clearance <60ml/min per 1.73 m2.
Undiagnosed chest pain or myocardial infarction, stroke or cardiovascular event within 3 months.
Pregnancy.
Subjects receiving chronic anticoagulant.
Inability to complete the 6 minute walk test.

Gender

Both

Ages

18 Years to 80 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact: Tammi F Lawther, BS

412-624-8295

lawthertf@upmc.edu

Location Countries ^ICMJE

United States

Administrative Information

NCT Number ^ICMJE

NCT01581086

Other Study ID Numbers ^ICMJE

VAST11060550

Has Data Monitoring Committee

Yes

Responsible Party

University of Pittsburgh

Study Sponsor ^ICMJE

University of Pittsburgh

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Principal Investigator:

Hunter C Champion, MD

University of Pittsburgh

Information Provided By

University of Pittsburgh

Verification Date

April 2012

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top